Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Periocular Pigmented Basal Cell Carcinomas: Clinicopathologic Features and Mutational Profile

Periocular Pigmented Basal Cell Carcinomas: Clinicopathologic Features and Mutational Profile Purpose: Pigmented basal cell carcinomas (PBCC) is an uncommon variant of basal cell carcinoma of the periocular region with limited information in the literature. We highlight the clinicopathological profile and somatic mutations in periocular PBCC. Methods: The clinicopathological features and somatic mutations in patients with periocular PBCC were examined and compared with periocular non-PBCC reported in the literature. Next-generation sequencing panel analysis for the excised tumors identified somatic mutations. Results: In a total of 31 patients, PBCC was common in females (54%; p = 0.03); as a unilateral lower eyelid (n = 22; 71%), solitary mass (n = 30; 98%). Pathologic subtypes were variable. Most were nodular or mixed variants (n = 23; 74%). During the follow up (2.5–4.5 years), 1 patient (3.5%) had a recurrence. The clinical and pathologic features of PBCC were similar to those reported in nonperiocular locations. Somatic mutations detected in 25/31 tumors. Variants in 50/161 genes in the panel were noted. PTCH1 (14/31), TERT (12/31), and SMO (7/31) variants were common. Fifteen patients had novel drivers, including POLE, FANCD2, and CREBBP. SMO mutations were significantly more common in females (7/7), lower eyelid (5/7), and TERT mutations were more common in nodular subtype (10/12). Conclusions: In this large cohort of a relatively uncommon variant of BCC, the clinicopathological features and tumor behavior of PBCC was similar to periocular non-PBCC. The somatic mutation spectrum of PBCC resembles that reported in nonperiocular cutaneous BCC with novel drivers identified. We identified several potential actionable mutations that could be targeted with molecular therapy. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Ophthalmic Plastic and Reconstructive Surgery Wolters Kluwer Health

Periocular Pigmented Basal Cell Carcinomas: Clinicopathologic Features and Mutational Profile

Download PDF
8 pages

Loading next page...
 
/lp/wolters-kluwer-health/periocular-pigmented-basal-cell-carcinomas-clinicopathologic-features-r0pfZ5viql

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
Copyright
© 2022 The American Society of Ophthalmic Plastic and Reconstructive Surgery, Inc.
ISSN
0740-9303
eISSN
1537-2677
DOI
10.1097/iop.0000000000002173
Publisher site
See Article on Publisher Site

Abstract

Purpose: Pigmented basal cell carcinomas (PBCC) is an uncommon variant of basal cell carcinoma of the periocular region with limited information in the literature. We highlight the clinicopathological profile and somatic mutations in periocular PBCC. Methods: The clinicopathological features and somatic mutations in patients with periocular PBCC were examined and compared with periocular non-PBCC reported in the literature. Next-generation sequencing panel analysis for the excised tumors identified somatic mutations. Results: In a total of 31 patients, PBCC was common in females (54%; p = 0.03); as a unilateral lower eyelid (n = 22; 71%), solitary mass (n = 30; 98%). Pathologic subtypes were variable. Most were nodular or mixed variants (n = 23; 74%). During the follow up (2.5–4.5 years), 1 patient (3.5%) had a recurrence. The clinical and pathologic features of PBCC were similar to those reported in nonperiocular locations. Somatic mutations detected in 25/31 tumors. Variants in 50/161 genes in the panel were noted. PTCH1 (14/31), TERT (12/31), and SMO (7/31) variants were common. Fifteen patients had novel drivers, including POLE, FANCD2, and CREBBP. SMO mutations were significantly more common in females (7/7), lower eyelid (5/7), and TERT mutations were more common in nodular subtype (10/12). Conclusions: In this large cohort of a relatively uncommon variant of BCC, the clinicopathological features and tumor behavior of PBCC was similar to periocular non-PBCC. The somatic mutation spectrum of PBCC resembles that reported in nonperiocular cutaneous BCC with novel drivers identified. We identified several potential actionable mutations that could be targeted with molecular therapy.

Journal

Ophthalmic Plastic and Reconstructive Surgery – Wolters Kluwer Health

Published: Sep 14, 2022

References

  • Risk factors for orbital exenteration in periocular Basal cell carcinoma.
    Iuliano, A; Strianese, D; Uccello, G
  • Clinical histopathological characteristics of basal cell carcinoma in Japanese patients.
    Kikuchi, A; Shimizu, H; Nishikawa, T
  • Pigmented basal cell carcinoma of the eyelid in Hispanics.
    Lin, LK; Lee, H; Chang, E
  • Clinical features and histologic pattern analysis of pigmented basal cell carcinomas in an Italian population.
    Betti, R; Gualandri, L; Cerri, A
  • Characteristics and Factors Related to Eyelid Basal Cell Carcinoma in Saudi Arabia.
    Al Wohaib, M; Al Ahmadi, R; Al Essa, D
  • Pigmented basal cell carcinoma: investigation of 70 cases.
    Maloney, ME; Jones, DB; Sexton, FM
  • Subclinical infiltration of Basal cell carcinoma in asian patients: assessment after mohs micrographic surgery.
    Ro, KW; Seo, SH; Son, SW
  • UV-specific p53 and PTCH mutations in sporadic basal cell carcinoma of sun-exposed skin.
    Ratner, D; Peacocke, M; Zhang, H
  • Unexpected manifestation of naevoid basal cell carcinoma (Gorlin) syndrome with a novel mutation in the PTCH1 gene in a female patient with long-lasting pemphigus vulgaris.
    Goetze, S; Raessler, F; Hipler, UC
  • Targeting Hedgehog signaling pathway: Paving the road for cancer therapy.
    Salaritabar, A; Berindan-Neagoe, I; Darvish, B
  • Sonic hedgehog signaling pathway and gallbladder cancer: targeting with precision medicine approach.
    Takebe, N; Yang, SX
  • GSK3β and Gli3 play a role in activation of Hedgehog-Gli pathway in human colon cancer - Targeting GSK3β downregulates the signaling pathway and reduces cell proliferation.
    Trnski, D; Sabol, M; Gojević, A
  • Clinical management and genomic profiling of pediatric low-grade gliomas in Saudi Arabia.
    Mobark, NA; Alharbi, M; Alhabeeb, L
  • Analytical validation of the next-generation sequencing assay for a nationwide signal-finding clinical trial: molecular analysis for therapy choice clinical trial.
    Lih, CJ; Harrington, RD; Sims, DJ
  • Understanding the molecular genetics of basal cell carcinoma.
    Pellegrini, C; Maturo, MG; Di Nardo, L
  • Nevoid basal cell carcinoma syndrome: PTCH1 mutation profile and expression of genes involved in the Hedgehog pathway in Argentinian patients.
    Martinez, MF; Romano, MV; Martinez, AP
  • A Novel PTCH1 frameshift mutation leading to nevoid basal cell carcinoma syndrome.
    Durmaz, CD; Evans, G; Smith, MJ
  • Whole-exome sequencing of nevoid basal cell carcinoma syndrome families and review of Human Gene Mutation Database PTCH1 mutation data.
    Gianferante, DM; Rotunno, M; Dean, M
  • Novel PTCH1 gene mutation in nevoid basal cell carcinoma syndrome.
    Sim, YC; Kim, GH; Choi, SW
  • Genetics of basal cell carcinoma.
    de Zwaan, SE; Haass, NK
  • TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma.
    Griewank, KG; Murali, R; Schilling, B
  • Mutations of the TERT promoter are common in basal cell carcinoma and squamous cell carcinoma.
    Scott, GA; Laughlin, TS; Rothberg, PG
  • The molecular genetics underlying basal cell carcinoma pathogenesis and links to targeted therapeutics.
    Iwasaki, JK; Srivastava, D; Moy, RL
  • Recurrent NMYC copy number gain and high protein expression in basal cell carcinoma.
    Freier, K; Flechtenmacher, C; Devens, F
  • Phenotype of POLE-mutated endometrial cancer.
    Imboden, S; Nastic, D; Ghaderi, M
  • Expression and prognostic significance of Fanconi anemia group D2 protein and breast cancer type 1 susceptibility protein in familial and sporadic breast cancer.
    Feng, L; Jin, F
  • Crebbp loss drives small cell lung cancer and increases sensitivity to HDAC inhibition.
    Jia, D; Augert, A; Kim, DW
  • Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma.
    Bonilla, X; Parmentier, L; King, B
  • A Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer [ClinicalTrial.gov identifier: 04177108].
  • INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies.
    van Tilburg, CM; Witt, R; Heiss, M
  • MEK inhibitors for the treatment of NRAS mutant melanoma.
    Sarkisian, S; Davar, D
  • Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.
    Rubinstein, MM; Hyman, DM; Caird, I
  • Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.
    Li, Y; Song, Q; Day, BW
  • Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma.
    Pricl, S; Cortelazzi, B; Dal Col, V
  • Acquired resistance to the Hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma.
    Brinkhuizen, T; Reinders, MG; van Geel, M